This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Andreu, E. J. Articles by Pérez-Roger, I. Search for Related Content PubMed PubMed Citation Articles by Andreu, E. J. Articles by Pérez-Roger, I.

BCR-ABL Induces the Expression of Skp2 through the PI3K Pathway to Promote p27^Kip1 Degradation and Proliferation of Chronic Myelogenous Leukemia Cells

¹ Division of Cancer, Area of Cell Therapy and Hematology Service, Clinica Universitaria/School of Medicine, Foundation for Applied Medical Research, University of Navarra, Pamplona; ² Departamento de Química, Bioquímica y Biología Molecular, Universidad Cardenal Herrera-CEU, Moncada; and ³ Servicio de Hematología y Oncología Médica, Hospital Clínico de Valencia, Valencia, Spain

Requests for reprints: Ignacio Pérez-Roger, Departamento de Química, Bioquímica y Biología Molecular, Universidad Cardenal Herrera-CEU, av. Seminario s/n, 46113 Moncada, Valencia, Spain. Phone: 34-96-1369000 (1233); Fax: 34-96-139-5272; E-mail: iperez{at}uch.ceu.es or Felipe Prósper, Servicio de Hematología, Area de Terapia Celular, Av Pio XII 36, 31080 Pamplona, Spain. Phone: 34-948-255400; Fax: 34-948-296500; E-mail: fprosper{at}unav.es.

Chronic myelogenous leukemia (CML) is characterized by the expression of the BCR-ABL tyrosine kinase, which results in increased cell proliferation and inhibition of apoptosis. In this study, we show in both BCR-ABL cells (Mo7e-p210 and BaF/3-p210) and primary CML CD34+ cells that STI571 inhibition of BCR-ABL tyrosine kinase activity results in a G₁ cell cycle arrest mediated by the PI3K pathway. This arrest is associated with a nuclear accumulation of p27^Kip1 and down-regulation of cyclins D and E. As a result, there is a reduction of the cyclin E/Cdk2 kinase activity and of the retinoblastoma protein phosphorylation. By quantitative reverse transcription-PCR we show that BCR-ABL/PI3K regulates the expression of p27^Kip1 at the level of transcription. We further show that BCR-ABL also regulates p27^Kip1 protein levels by increasing its degradation by the proteasome. This degradation depends on the ubiquitinylation of p27^Kip1 by Skp2-containing SFC complexes: silencing the expression of Skp2 with a small interfering RNA results in the accumulation of p27^Kip1. We also demonstrate that BCR-ABL cells show transcriptional up-regulation of Skp2. Finally, expression of a p27^Kip1 mutant unable of being recognized by Skp2 results in inhibition of proliferation of BCR-ABL cells, indicating that the degradation of p27^Kip1 contributes to the pathogenesis of CML. In conclusion, these results suggest that BCR-ABL regulates cell cycle in CML cells at least in part by inducing proteasome-mediated degradation of the cell cycle inhibitor p27^Kip1 and provide a rationale for the use of inhibitors of the proteasome in patients with BCR-ABL leukemias.

This article has been cited by other articles:

				I. Hirano, S. Nakamura, D. Yokota, T. Ono, K. Shigeno, S. Fujisawa, K. Shinjo, and K. Ohnishi Depletion of Pleckstrin Homology Domain Leucine-rich Repeat Protein Phosphatases 1 and 2 by Bcr-Abl Promotes Chronic Myelogenous Leukemia Cell Proliferation through Continuous Phosphorylation of Akt Isoforms J. Biol. Chem., August 14, 2009; 284(33): 22155 - 22165. [Abstract] [Full Text] [PDF]

				J. Xiao, S. Yin, Y. Li, S. Xie, D. Nie, L. Ma, X. Wang, Y. Wu, and J. Feng SKP2 siRNA inhibits the degradation of P27kip1 and down-regulates the expression of MRP in HL-60/A cells Acta Biochim Biophys Sin, August 1, 2009; 41(8): 699 - 708. [Abstract] [Full Text] [PDF]

				X.-C. Wang, Y.-P. Wu, B. Ye, D.-C. Lin, Y.-B. Feng, Z.-Q. Zhang, X. Xu, Y.-L. Han, Y. Cai, J.-T. Dong, et al. Suppression of Anoikis by SKP2 Amplification and Overexpression Promotes Metastasis of Esophageal Squamous Cell Carcinoma Mol. Cancer Res., January 1, 2009; 7(1): 12 - 22. [Abstract] [Full Text] [PDF]

				X. Agirre, A. Jimenez-Velasco, E. San Jose-Eneriz, L. Garate, E. Bandres, L. Cordeu, O. Aparicio, B. Saez, G. Navarro, A. Vilas-Zornoza, et al. Down-Regulation of hsa-miR-10a in Chronic Myeloid Leukemia CD34+ Cells Increases USF2-Mediated Cell Growth Mol. Cancer Res., December 1, 2008; 6(12): 1830 - 1840. [Abstract] [Full Text] [PDF]

				S. Monteghirfo, F. Tosetti, C. Ambrosini, S. Stigliani, S. Pozzi, F. Frassoni, G. Fassina, S. Soverini, A. Albini, and N. Ferrari Antileukemia effects of xanthohumol in Bcr/Abl-transformed cells involve nuclear factor-{kappa}B and p53 modulation Mol. Cancer Ther., September 1, 2008; 7(9): 2692 - 2702. [Abstract] [Full Text] [PDF]

				A. Agarwal, T. G. P. Bumm, A. S. Corbin, T. O'Hare, M. Loriaux, J. VanDyke, S. G. Willis, J. Deininger, K. I. Nakayama, B. J. Druker, et al. Absence of SKP2 expression attenuates BCR-ABL-induced myeloproliferative disease Blood, September 1, 2008; 112(5): 1960 - 1970. [Abstract] [Full Text] [PDF]

				M. Reichert, D. Saur, R. Hamacher, R. M. Schmid, and G. Schneider Phosphoinositide-3-Kinase Signaling Controls S-Phase Kinase-Associated Protein 2 Transcription via E2F1 in Pancreatic Ductal Adenocarcinoma Cells Cancer Res., May 1, 2007; 67(9): 4149 - 4156. [Abstract] [Full Text] [PDF]

				P. Sinai, R. E. Berg, J. M. Haynie, M. J. Egorin, R. L. Ilaria Jr, and J. Forman Imatinib Mesylate Inhibits Antigen-Specific Memory CD8 T Cell Responses In Vivo J. Immunol., February 15, 2007; 178(4): 2028 - 2037. [Abstract] [Full Text] [PDF]

				L. Moro, A. A. Arbini, E. Marra, and M. Greco Up-regulation of Skp2 after Prostate Cancer Cell Adhesion to Basement Membranes Results in BRCA2 Degradation and Cell Proliferation J. Biol. Chem., August 4, 2006; 281(31): 22100 - 22107. [Abstract] [Full Text] [PDF]

				W. Fiskus, M. Pranpat, P. Bali, M. Balasis, S. Kumaraswamy, S. Boyapalle, K. Rocha, J. Wu, F. Giles, P. W. Manley, et al. Combined effects of novel tyrosine kinase inhibitor AMN107 and histone deacetylase inhibitor LBH589 against Bcr-Abl-expressing human leukemia cells Blood, July 15, 2006; 108(2): 645 - 652. [Abstract] [Full Text] [PDF]

				K. Wolanin, A. Magalska, G. Mosieniak, R. Klinger, S. McKenna, S. Vejda, E. Sikora, and K. Piwocka Curcumin Affects Components of the Chromosomal Passenger Complex and Induces Mitotic Catastrophe in Apoptosis-Resistant Bcr-Abl-Expressing Cells Mol. Cancer Res., July 1, 2006; 4(7): 457 - 469. [Abstract] [Full Text] [PDF]

				C. Carella, M. Potter, J. Bonten, J. E. Rehg, G. Neale, and G. C. Grosveld The ETS factor TEL2 is a hematopoietic oncoprotein Blood, February 1, 2006; 107(3): 1124 - 1132. [Abstract] [Full Text] [PDF]